Ahmadi Parisa, Akbarzadeh Samad, Alizadeh Mehdi, Mohammadi Neshat, Mahmoodi Marzieh, Amini Azam, Netticadan Thomas, Rezaei Mikaeil, Movahed Ali
Bushehr University of Medical Sciences, Bushehr, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Mol Cell Biochem. 2025 Jul 17. doi: 10.1007/s11010-025-05351-7.
Cardiovascular diseases (CVD), especially coronary artery disease (CAD), are among the most important causes of mortality in the world. Coronary artery bypass grafting (CABG) is a standard treatment for this disease, but it may be associated with complications in the postoperative period. This study investigated the effect of resveratrol (RES), a potent antioxidant and anti-inflammatory molecule, on cardiovascular indices and oxidative stress in patients after CABG surgery. This randomized, double-blind, placebo-controlled trial was carried out at the Bushehr Heart Center in Bushehr, Iran. A total of 60 patients undergoing CABG were randomly assigned in equal numbers to either the intervention group or the control group. The intervention group received RES capsules for 60 days, and the control group received a placebo for the same duration. Cardiovascular function and biochemical parameters, including lipid profile, cardiac enzymes, and markers of oxidative stress and inflammation, were measured at the beginning and end of the intervention. Compared to the control group, RES intake significantly reduced systolic blood pressure (SBP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and improved ejection fraction (EF). Although decreases in cardiac enzymes, including creatine phosphokinase (CPK) and lactate dehydrogenase (LDH), were observed in the RES group, these changes were not statistically significant. Also, the two groups showed no significant differences in diastolic blood pressure (DBP), HDL, or oxidative stress markers. RES supplementation protects patients after CABG by improving cardiovascular function and lipid profiles.Trial registration: IRCT20111119008129N12, first trial registration date: 2022-06-18.
心血管疾病（CVD），尤其是冠状动脉疾病（CAD），是全球最重要的死亡原因之一。冠状动脉旁路移植术（CABG）是这种疾病的标准治疗方法，但术后可能会出现并发症。本研究调查了白藜芦醇（RES），一种有效的抗氧化和抗炎分子，对CABG手术后患者心血管指标和氧化应激的影响。这项随机、双盲、安慰剂对照试验在伊朗布什尔的布什尔心脏中心进行。共有60例接受CABG的患者被随机平均分为干预组或对照组。干预组接受RES胶囊60天，对照组在相同时间内接受安慰剂。在干预开始和结束时测量心血管功能和生化参数，包括血脂谱、心肌酶以及氧化应激和炎症标志物。与对照组相比，摄入RES可显著降低收缩压（SBP）、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白（LDL），并改善射血分数（EF）。虽然RES组的心肌酶，包括肌酸磷酸激酶（CPK）和乳酸脱氢酶（LDH）有所下降，但这些变化无统计学意义。此外，两组在舒张压（DBP）、高密度脂蛋白（HDL）或氧化应激标志物方面无显著差异。补充RES可通过改善心血管功能和血脂谱来保护CABG术后的患者。试验注册号：IRCT20111119008129N12，首次试验注册日期：2022年6月18日。
